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Presenilin, the catalytic component of the -secretase complex,
type IV prepilin peptidases, and signal peptide peptidase (SPP) are
the founding members of the family of intramembrane-cleaving
GXGD aspartyl proteases. SPP-like (SPPL) proteases, such as
SPPL2a, SPPL2b, SPPL2c, and SPPL3, also belong to the GXGD
family. In contrast to -secretase, for which numerous substrates
have been identified, very few in vivo substrates are known for SPP
and SPPLs. Here we demonstrate that Bri2 (Itm2b), a type II-ori-
ented transmembrane protein associated with familial British and
Danish dementia, undergoes regulated intramembrane proteoly-
sis. In addition to the previously described ectodomain processing
by furin and related proteases, we now describe that the Bri2 pro-
tein, similar to -secretase substrates, undergoes an additional
cleavage by ADAM10 in its ectodomain. This cleavage releases a
soluble variant of Bri2, the BRICHOS domain, which is secreted
into the extracellular space. Upon this shedding event, a mem-
brane-boundBri2N-terminal fragment remains,whichundergoes
intramembrane proteolysis to produce an intracellular domain as
well as a secreted low molecular weight C-terminal peptide. By
expressing all known SPP/SPPL family members as well as their
loss of function variants, we demonstrate that selectively SPPL2a
andSPPL2bmediate the intramembranecleavage,whereasneither
SPP nor SPPL3 is capable of processing the Bri2 N-terminal
fragment.
Regulated intramembrane proteolysis (RIP)4 describes a
novel cellular mechanism that explains how type I or type II
transmembrane proteins are proteolytically processed (1, 2).
RIP is required for reverse signaling and degradation of mem-
brane-retained stubs of certain substrates (1). In a typical exam-
ple, RIP describes two proteolytic processing steps. First, a large
part of the ectodomain is shed and secreted. Subsequently,
intramembrane proteolysis cleaves the remaining membrane-
bound fragment into two peptides, the intracellular domain
(ICD) and a small peptide, which is secreted. Until recently,
proteolysis within the membrane was believed to be rather
impossible because water molecules, known to be required for
hydrolysis of peptide bonds, may have difficulties to penetrate
the hydrophobic membrane. However, currently members of
three different intramembrane-cleaving protease families are
known. All are polytopic proteins with their catalytic sites most
likely embedded within their transmembrane domains (1).
Intramembrane-cleaving metalloproteases are represented by
the site-2 protease (3–5). Site-2 protease (S2P) is required for
the regulation of cholesterol and fatty acid biosynthesis via the
liberation of the membrane-bound transcription factor sterol
regulatory element-binding protein (SREBP) by intramem-
brane proteolysis. In addition, site-2 protease is also involved in
intramembrane processing of ATF6, a protein required for
chaperone expression during unfolded protein response. Prior
to intramembrane cleavage, both substrates are first shed by a
luminal cleavage via site-1 protease (6).
Intramembrane-cleaving serine proteases are represented by
the growing family of rhomboids. At least Drosophila rhom-
boids are known to be involved in intramembrane proteoly-
sis of Spitz, Gurken, and Keren. Their cleavage is required
for epidermal growth factor receptor signaling (7–9), but an
initiating shedding event is apparently not required. Rhom-
boids are the first intramembrane-cleaving proteases for
which crystal structures could be resolved (10–14). The
crystal structures suggest that their catalytically active Ser-
His dyad and water molecules are indeed embedded within
the interior of the membrane.
The family of intramembrane-cleaving aspartyl proteases is
represented by -secretase, the signal peptide peptidase (SPP)
(15), its homologues the SPP-like (SPPL) proteases (1, 16–18),
and the bacterial type IV prepilin peptidases, which cleave very
close to or right at the membrane (19).
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-Secretase is a complex composed of presenilin-1 or prese-
nilin-2, nicastrin, APH-1 (anterior pharynx defective-1), and
PEN-2 (presenilin enhancer-2) (20). Presenilin is the catalyti-
cally active component of the -secretase complex (21) and
contains the GXGD protease active site motif (22). -Secre-
tase cleaves numerous type I substrates including Notch
and the -amyloid precursor protein (20, 23, 24). In both
cases, the ICDs of the substrates are released to the cytosol.
Although the Notch ICD is required for reverse signaling, a
functional role of the -amyloid precursor protein ICD is cur-
rently under debate (20, 24), and for a number of other sub-
strates the function of the ICD is unknown. Besides the ICDs,
-secretase also liberates the amyloid -peptide and the corre-
sponding Notch -peptide (25). Amyloid -peptide accumu-
lates in amyloid plaques and vascular deposits characteristic for
Alzheimer disease. Although -secretase only accepts type
I-oriented substrates, members of the SPP family are required
for intramembrane proteolysis of type II transmembrane pro-
teins (1). SPP family members are differentially located within
the cells (26, 27). SPP and SPPL3 are predominantly observed
within the endoplasmic reticulum (ER)/Golgi, whereas SPPL2a
and SPPL2b are additionally found in late Golgi compartments
and endosomes/lysosomes (26). Consistent with its subcellular
localization, SPP is required for the removal of signal peptides
from the ER membrane (15). Beside its function in removal of
signal peptides, SPP is also involved in immune surveillance and
intramembrane cleavage of the hepatitis C viral core protein
(15, 28). No substrate has so far been identified for the ER/Golgi
located SPPL3. For SPPL2a and SPPL2b currently two in vivo
substrates, tumor necrosis factor  (TNF) and the Fas ligand,
are known (27, 29, 30).
The ectodomains of both substrates undergo shedding by
members of the ADAM (a disintegrin and metalloprotease)
family. TNF is further processed by intramembrane cleavages
of SPPL2a/SPPL2b to produce the TNF ICD and the secreted
TNFCdomain (29). TheTNF ICD triggers expression of the
pro-inflammatory cytokine interleukin-12 in dendritic cells
(27). Because of the restricted cell and tissue specific expression
of TNF and FasL, additional substrates for SPPL2a/SPPL2b
are to be expected.
We therefore investigated the type II-oriented transmem-
brane protein Bri2, also known as Itm2b, which is the precursor
of the ABri amyloid protein (31). For clarity, we will use the
term Bri2 throughout the manuscript. Bri2 undergoes process-
ing by furin and related proteases within its ectodomain (32,
33), which leads to the release of its 4-kDa C-terminal propep-
tide. Mutations of the stop codon in the bri2 (itm2b) gene are
responsible for the generation of a longer open reading frame,
therefore causing the release of a longer propeptide by furin-me-
diated proteolysis (31–33). The mutant Bri2 amyloid propep-
tides (ABri) tend to aggregate into oligomers, protofibrils, and
further into amyloid deposits and cause familial British (31) and
Danish dementia (34), which are autosomal dominant neuro-
degenerative diseases characterized by amyloid angiopathy,
plaques, and neurofibrillar tangles (33, 35).
We have now investigated the proteolytic processing of Bri2.
Surprisingly, in addition to the furin-mediated release of the
C-terminal propeptide, a large part of the remaining ectodo-
main, the so-called BRICHOSdomain, is shed byADAM10 and
released to the extracellular space. The remaining membrane-
associated N-terminal fragment (NTF) undergoes intramem-
brane proteolysis mediated by SPPL2a or SPPL2b. This cleav-
age generates the Bri2 ICD, which is liberated into the cytosol
and the secreted Bri2 C domain.
EXPERIMENTAL PROCEDURES
Cell Culture, cDNAs, and Transfection—HEK293EBNA,
HEK293TR, and SH-SY5Y cells were cultured in Dulbecco’s
modified Eagle’s medium with Glutamax (Invitrogen) supple-
mented with 10% fetal calf serum (Invitrogen) and 1% penicil-
lin/streptomycin (Invitrogen). SNKBE cells were cultured in
Ham’s F-12medium (Cambrex Bio Science, Verviers, Belgium)
supplemented with 2.5% non-essential amino acids (Invitro-
gen) and 10% fetal calf serum. A-431 cells were cultured in
AdvancedRPMI 1640medium (Invitrogen) supplementedwith
0.5% penicillin/streptomycin and 10% fetal calf serum. Using
PCR, a C-terminal HA tag (AYPYDVPDYA) was added to all
constructs. SPPL2a, SPPL2a D412A, SPPL2b, SPPL2b D421A,
and SPPL3 D272A were subcloned into the NheI and NotI or
EcoRI and XhoI sites of pcDNA 3.1. Zeo (Invitrogen) and
stably transfected into HEK293EBNA cells. SPP, SPP D265A,
and SPPL3 were subcloned into the EcoRI and XhoI sites of
pcDNA 4/TO A (Invitrogen) and stably transfected into
HEK293 TR cells (Invitrogen). Transfection of cells was carried
out using Lipofectamine 2000 (Invitrogen) according to the
manufacturer’s instructions, and single cell clones were gener-
ated by selection in 200 g/ml zeocine (Invitrogen). To induce
expression of SPP, SPPD265A, and SPPL3, cells were incubated
with 1 g/ml doxycycline (BD Biosciences) added to the cell
culture medium for at least 48 h.
Bri2 cDNA was purchased from RZPD (Deutsches Ressou-
rcezentrum für Genomforschung, Berlin, Germany). After the
starting methionine an N-terminal FLAG tag (DYKDDDDK)
and, at the C terminus of the protein, a V5 tag (GKPIPNPLL-
GLDST) were added, and the PCR product was subcloned into
theHindIII andXbaI sites of pcDNA6.0-V5-His A (Invitrogen).
The Bri2E and the Bri2FC constructs were generated by
deleting the C-terminal part of the protein after amino acids 94
and 240, respectively. The Bri2 KR 243/244 AA (KR/AA) con-
struct was generated by PCR mutagenesis. These Bri2 con-
structs also contain an N-terminal FLAG tag and a C-terminal
V5 tag and were subcloned into the HindIII and XbaI sites of
pcDNA6.0-V5-His A (Invitrogen). All cDNA constructs were
sequenced for verification. Bri2 cDNAs were either transiently
or stably expressed in cell lines stably expressing SPPs or SPPLs
as described above.
Antibodies, Immunoprecipitation, and Immunoblotting—
The anti-HA peroxidase-coupled 3F10 antibody was obtained
from Roche Diagnostics. The monoclonal anti-FLAG M2 and
the polyclonal HA 6908 antibody were obtained from Sigma.
Polyclonal andmonoclonal V5 antibodieswere purchased from
Chemicon (Schwalbach, Germany) and Invitrogen, respec-
tively. The polyclonal antibodies against ADAM10, Calnexin,
and ADAM17 (TACE) were purchased from Calbiochem,
Stressgene/Biomol (Hamburg, Germany), and Oncogene,
respectively. The polyclonal anti-Bri2 antibody (ITM2b
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ab14307) directed against the first 60 amino acids of human
Bri2 was obtained from Abcam (Cambridge, UK). The mono-
clonal SPPL2b-specific antibody CADG-3F9 directed against
amino acids 518–535 of the protein was established by
Dr. Elisabeth Kremmer (GSF-Forschungszentrum, Munich).
Anti-mouse, anti-rabbit, and anti-chicken peroxidase second-
ary antibodies were purchased from Promega (Madison).
Immunoprecipitation assays, gel electrophoresis, immunoblot-
ting experiments, and co-immunoprecipitation assays were
carried out as described previously (26, 29).
Immunocytochemistry andConfocal Imaging—The indicated
cell lines were grown on polylysine-coated glass coverslips to
50–80% confluence and processed for immunofluorescence as
described before (26). Confocal images were obtained with
Zeiss 510Meta confocal laser scanning microscope system
equipped with a 100/1.3 objective described previously (36).
Images were assembled and processed using Adobe Illustrator.
Inhibitor Treatment and RNA Interference—To inhibit
SPPL2b, cells were treated overnight with a final concentration
of 15 M (Z-LL)2-ketone (Calbiochem), a known SPP inhibitor
(37). As a control, cells were treated with 3 M -secretase
inhibitor DAPT (38) or the respective carrier.
To block specificmetalloprotease activities, cells were grown
in a 6-well format and treated overnight with either 50 M
TAPI-1 (Peptides International) or 50 M TAPI-2 (Peptides
International). Hydroxamate-based inhibitors GW280264 (5
M) and GI254023 (5 M) are described elsewhere (39).
For quantification, proteins were immunoblotted as
described above and detected using the enhanced chemilumi-
nescence technique (GE Healthcare). The chemiluminescence
signals of at least three independent experiments were meas-
ured with a CD camera-based imaging system (Alpha-Innotec,
Kasendorf, Germany). Statistical significance was determined
with Student’s t test. Statistically significantp values of0.05 or
0.005 are represented by or, respectively.
RNA interference experiments were carried out as follows.
1  106 cells/well were plated in a polylysine-coated 6-well
format. After a 2-h incubation, cells were transfected with the
indicated small interfering RNA (siRNA) (Dharmacon siRNA
SMARTpools: catalog numbers M-0040503-01 (ADAM10),
M-003453-00 (ADAM17), and D-001206-13 (non-targeting
control)), using Lipofectamine 2000 (Invitrogen) according to
the manufacturer’s instructions. 24 h after transfection, the
medium was exchanged, and cells were harvested 48 h after
transfection. Five independent experiments were quantified as
described above. BRICHOS and Bri2FC levels were first nor-
malized to the calnexin expression level, and then the ratio of
BRICHOS to Bri2FC was determined. Resulting data for con-
trol siRNA were set to 100%.
Where indicated cells were treated overnight with 10 g/ml
brefeldinA (BFA; Sigma-Aldrich). As a control, cells were incu-
bated with the respective carrier.
RESULTS
Shedding of Bri2 by ADAM10—The Bri2 protein is a type II
transmembrane protein, known to be processed within its
ectodomain by furin and related proteases (Fig. 1A, proBri2)
(32, 33, 40). Consequently, a membrane-bound fragment, con-
taining the so-called BRICHOS domain, remains after this ini-
tial processing (Fig. 1A, Bri2). As expected, Bri2 containing the
propeptide (pro-Bri2) was detected at a molecular mass of 50
kDa in all cell lines tested. The mature Bri2 variant lacking the
propeptide (Bri2) was detected at a slightly lower molecular
weight and was most prominently visible in cell lines of neuro-
nal origin (Fig. 1B, SKNBE, SH-SY5Y). However, besides these
expected Bri2 species, we additionally detected a lower molec-
ularmass Bri2NTF of22 kDa in all cell lines investigated (Fig.
1B). We therefore assumed that Bri2 might undergo shedding
because such a proteolytic processing step would result in the
generation of a small membrane retained stub (Fig. 1A, NTF).
If such a shedding event takes place, one would expect a
secreted counterpart containing the BRICHOS domain (see
Fig. 1A). To allow identification of such a secreted domain, we
inserted a V5 tag directly at the C terminus of the BRICHOS
domain generating Bri2FC (Fig. 2A). Upon expression of this
cDNA construct, we indeed detected the 25-kDa BRICHOS
domain as a secreted species in the conditioned medium (Fig.
2B). Similar to cells expressing endogenous Bri2 (Fig. 1B), NTF
was observed within the cell lysate (Fig. 2B). This suggests that
the BRICHOS domain and the Bri2 NTF are generated by a
novel shedding event of Bri2 andmay explain the observation of
a N-terminal Bri2 fragment of unknown origin by Choi et al.
(40). In analogy to many -secretase substrates, which require
shedding by proteases of the ADAM family, we investigated
whether a member of this protease family is involved in shed-
ding of Bri2. Broad ADAM protease inhibitors, such as TAPI-1
and TAPI-2 (41), strongly reduced the secretion of the BRI-
CHOS domain (Fig. 2C). The nature of the metalloprotease
activity was narrowed down using two hydroxamate-based
inhibitors that differ in their inhibitory profile. The inhibitor
GW280264X has been shown to block ADAM17 and
ADAM10, whereas the compound GI254023X preferentially
blocks ADAM10 (39). Both inhibitors strongly blocked secre-
tion of the BRICHOS domain (Fig. 2D). To finally determine
which of the two proteases is required for shedding of Bri2, we
selectively knocked down ADAM10 and ADAM17 using RNA
interference techniques. Upon transient knockdown of
ADAM10, secretion of the BRICHOS domain was significantly
reduced compared with cells treated with a control RNA inter-



































FIGURE 1. Proteolytic processing of Bri2. A, schematic presentation of Bri2
processing by furin (or related proteases) and a sheddase. B, proteolytic proc-
essing of endogenous Bri2. Membrane preparations of human embryonic
kidney cells (HEK293/TRex), SKNBE cells, SH-SY5Y cells, and A431 cells were
analyzed using the anti-Bri2 antibody (ITM2b ab14307) directed against the
first 60 amino acids of human Bri2. Besides the expected Bri2 variants (pro-
Bri2/Bri2), an additional Bri2 NTF of 22 kDa was detected in all cell lines.
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other hand did not have a significant effect on the secretion
of the BRICHOS domain. A combined knockdown of
ADAM10 and ADAM17 failed to further reduce BRICHOS
secretion (Fig. 2E). Taken together, these data demonstrate
that Bri2 undergoes ectodomain shedding via proteolytic
processing by ADAM10.
Bri2 Is a Substrate for Intramembrane Proteolysis by SPPL2a
and SPPL2b—Ectodomain shedding produces membrane-re-
tained stubs that frequently undergo additional processing
within their transmembrane domains to either remove the
membrane-bound stub or to induce nuclear signaling (see
Introduction). To investigate whether Bri2 is also a substrate
for intramembrane proteolysis, we expressed the full-length
pro-Bri2 protein in HEK293 cells and investigated the proteo-
lytic processing by an immunoprecipitation analysis (Fig. 3B).
Interestingly, in addition to pro-Bri2, Bri2, and NTF, we
detected a fragment of10 kDa (ICD) in the cell lysate (Fig. 3B)
suggesting that the NTF may be further processed. Impor-
tantly, NTF and ICD generation occurs via processing by
endogenous proteases, and the Bri2 substrate has not been
modified at any cleavage site. ICD generation suggests that Bri2
undergoes proteolysis by an intramembrane-cleaving protease.
Because Bri2 is a type II-oriented protein, obvious candidates
for intramembrane proteolysis are the members of the SPP/
SPPL family. Todeterminewhether any of the SPP familymem-
bers could mediate intramembrane proteolysis of Bri2, we co-
expressed SPP, SPPL2a, SPPL2b, and SPPL3 with the full-
length Bri2 protein in HEK293 cells. In addition, the
catalytically inactive variants with the corresponding TM7
aspartate mutated to alanine (D/A mutants) (26) were also
investigated. The pro-Bri2 protein was expressed with a C-ter-




















































































































































FIGURE 2. Shedding of Bri2 by ADAM10. A, schematic presentation of Bri2FC. Bri2FC lacks the C-terminal propeptide. The V5 tag was inserted at amino acid
240 of Bri2. B, proteolytic processing of Bri2FC. Cell lysates and the conditioned medium of HEK293 cells stably expressing Bri2FC were analyzed for the
indicated processing products. Bri2FC was detected as a single band of 50 kDa using the anti-FLAG antibody. In addition the above described (Fig. 1B) NTF
of 22-kDa NTF was detected in the cell lysate. The potentially N-glycosylated BRICHOS domain was observed in the conditioned medium as an 25-kDa
peptide using the V5 antibody. C, TAPI treatment reduces BRICHOS secretion. HEK293 cells stably expressing Bri2FC were treated with 50 M TAPI-1 or TAPI-2
overnight. Control cells were treated with carrier (Me2SO) only. Compared with controls, cells treated with the TAPI-1 and TAPI-2 show a significantly reduced
(71  11.2%, p  0.001, and 78  10.2%, p  0.001, respectively) BRICHOS secretion. Detection of Bri2FC was used as a loading control (lower panel).
D, selective ADAM10/ADAM17 inhibitors reduce BRICHOS secretion. HEK293 cells stably expressing Bri2FC were treated with 5 M ADAM10 or ADAM10- and
ADAM17-specific inhibitor GI254023X or GW280264X, respectively, overnight. GI254023X and GW280264X cause a significantly reduced liberation of the
BRICHOS domain (73  8%, p  0.010, and 83  3%, p  0.015, respectively). E, ADAM10 is the BRICHOS sheddase. HEK293 cells stably expressing Bri2FC were
transfected with specific siRNA against ADAM10, ADAM17, or a nonspecific siRNA as a control. Knockdown efficiency was proven by immunoblotting for
ADAM10 and ADAM17. Detection of calnexin serves as a loading control. BRICHOS liberation was strongly reduced upon knockdown of ADAM10 or both
ADAM10 and ADAM17 (60  13%, p  0.001, and 40  11%, p  0.017, respectively). Knockdown of ADAM17 alone does not reduce the secretion of the
BRICHOS domain, indicating that ADAM10 is the major Bri2 sheddase. Note that the knockdown efficiency of ADAM10 in double knockdown experiments is
slightly reduced, allowing a stronger BRICHOS secretion compared with the single ADAM10 knockdown.
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proteolytic processing products from both ends (Fig. 3A). Con-
sistent with previous findings, the prodomain of Bri2 is proteo-
lytically removed (32, 33). Immunoblotting of cell lysates with
an antibody to the N-terminal FLAG tag revealed both Bri2,
lacking the C-terminal propeptide, and pro-Bri2 still contain-
ing the propeptide (Fig. 3C). In contrast, the antibody to the
C-terminal V5 tag selectively detects pro-Bri2 in the cell lysate
(Fig. 3C, upper panel). In addition, the tagged 5-kDa propeptide
was found to be released and secreted into the media of all
cell lines (Fig. 3C). Removal of the prodomain occurs inde-
pendently of whether and which SPP/SPPL was expressed or
not (Fig. 3C). Robust amounts
of the 10-kDa N-terminal fragment
corresponding to the ICD of Bri2
were detected in cell lysates only
upon expression of SPPL2a and
SPPL2b (Fig. 3C). In contrast, no
increase in ICD generation above
the background level was detectable
upon expression of SPP or SPPL3
(Fig. 3C). Increased amount of ICD
was only produced in the presence
of catalytically active SPPL2a/
SPPL2b, and its production was
abolished upon expression of the
catalytically inactive D/A mutants
of SPPL2a and SPPL2b (Fig. 3C).
Note that longer exposure reveals
the ICD generated by endogenous
processing (compare Fig. 3, B and
C). We concluded that this frag-
ment might be produced via
intramembrane proteolysis by
SPPL2a and SPPL2b, and therefore
we investigated whether SPPL2a/
SPPL2b may directly interact with
the Bri2 substrate. Co-immunopre-
cipitation allowed the co-isolation
of the 22-kDa NTF as well as of the
furin-generated Bri2 protein and
the full-length pro-Bri2 together
with SPPL2a/SPPL2b (Fig. 3D).
NTF co-immunoprecipitated at
high levels when the inactive D/A
mutation of SPPL2a or SPPL2b was
co-expressed (Fig. 3D), which is
similar to the accumulating C-ter-
minal fragments of -secretase sub-
strates upon its inhibition (42). In
line with these findings, the NTF
accumulated upon treatment with
(Z-LL)2-ketone, a selective SPP/
SPPL inhibitor (15), but not with
the -secretase inhibitor DAPT
(38). Furthermore, (Z-LL)2-ketone
inhibits ICD generation, as does
expression of the catalytically inac-
tive SPPL2b D/A mutant (Fig. 3E).
To prove whether Bri2 lacking its ectodomain is sufficient
for SPPL2 cleavage, we generated a recombinant Bri2 NTF
(Fig. 3A, Bri2E) corresponding to the NotchE construct
previously used to investigate -secretase function (43).
Expression of this construct was sufficient to allow SPPL2a/
SPPL2b-dependent ICD formation of Bri2 (Fig. 3F). More-
over, in the conditioned medium of cells expressing Bri2E,
we detected the secreted counterpart of the ICD, which we
called Bri2 C domain (Fig. 3, A and F). Both, ICD and C
domain generation are blocked upon expression of the D/A














































































































































































































FIGURE 3. Bri2 is a substrate for intramembrane proteolysis by SPPL2a and SPPL2b. A, schematic presen-
tation of pro-Bri2 and Bri2E. Bri2 constructs are N-terminally FLAG-tagged and C-terminally V5-tagged. The
Bri2E construct lacks the BRICHOS ectodomain and the propeptide. B, detection of a 10-kDa N-terminal
intracellular fragment. Pro-Bri2 was stably overexpressed in HEK293 cells. Cell lysates were immunoprecipi-
tated using the anti-FLAG antibody and were subjected to SDS-PAGE and Western blot analysis. As described
in the legends for Figs. 1B and 2B, a NTF of 22 kDa was detected. In addition, another intracellular fragment
of about 10 kDa (ICD) was detected after longer exposure. Note that the proteolytic products of Bri2 (NTF, ICD;
mature Bri2) were generated by endogenous proteases. C, proteolytic processing of Bri2 by SPPL2a and
SPPL2b. HEK293 cells stably expressing SPP, SPPL2a, SPPL2b, and SPPL3, or the respective catalytically inactive
D/A mutants were transiently transfected with pro-Bri2. Cell lysates and the conditioned media were immu-
noprecipitated using antibodies against the FLAG tag and the V5 tag, respectively, and were subsequently
subjected to SDS-PAGE and Western blot analysis. The indicated Bri2 fragments were detected using antibod-
ies against the indicated tags. In all cells lines, the propeptide was secreted into the conditioned medium. Using
an antibody against the C-terminal V5 tag, pro-Bri2 was detected as a single band in the cell lysates, whereas
pro-Bri2 and the furin-processed mature Bri2 were detected as a double band with an antibody directed
against the N-terminal FLAG tag. An additional 10-kDa anti-FLAG positive band (Bri2 ICD) was detected in
cells expressing SPPL2a or SPPL2b but not in cells expressing SPP, SPPL3, or the catalytically inactive mutants.
Upon longer exposure, the endogenously produced ICD was also detected as shown in B. D, co-immunopre-
cipitation of Bri2 and SPPL2a/SPPL2b. HEK293 cells expressing SPPL2a/SPPL2b or the inactive mutants SPPL2a/
SPPL2b D/A were transiently transfected with pro-Bri2. Immunoprecipitation of SPPL2a or SPPL2b, using an
anti-HA antibody, and detection of Bri2, using an anti-FLAG antibody, revealed binding of pro-Bri2, Bri2, and
the Bri2 NTF to SPPL2a (longer exposure) and SPPL2b. E, pharmacological inhibition of SPPL2b prevents Bri2
ICD generation. HEK293 cells stably expressing the indicated SPPL variants and pro-Bri2 were treated as indi-
cated with 15 M (Z-LL)2-ketone or 3 M DAPT overnight. Control cells were treated with Me2SO. Bri2 ICD
formation was inhibited by the SPP/SPPL-specific inhibitor (Z-LL)2-ketone but not by the -secretase inhibitor
DAPT. Note the accumulation of the NTF upon (Z-LL)2-ketone treatment and expression of catalytically inactive
SPPL2b variant (SPPL2b D/A). F, proteolytic processing of Bri2E by SPPL2a and SPPL2b. HEK293 cells stably
expressing the indicated SPPL variants were transiently transfected with BriE. Cell lysates and conditioned
media were analyzed for Bri2-specific fragments using antibodies against the FLAG tag and the V5 tag, respec-
tively. The Bri2E construct was processed by SPPL2a and SPPL2b, giving rise to the Bri2 ICD and a secreted C
domain. The catalytically inactive mutants do not process Bri2E and fail to generate the ICD and the C domain.
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Shedding by ADAM10 and Intramembrane Cleavage by
SPPL2b Occur Independently of a Prior Cleavage of Bri2
by Furin—Next, we investigated whether shedding of Bri2 by
ADAM10 requires a previous cut by furin. Therefore we
blocked the furin cleavage of Bri2 by mutagenizing the corre-
sponding cleavage site at amino acid 243/244 (33) generating
Bri2KR/AA (Fig. 4A). In cells expressing the mutant
Bri2KR/AA protein, no propeptide was detected in the condi-
tioned medium, but an 30-kDa fragment corresponding to a
peptide containing the BRICHOS domain and the propeptide
was observed (Fig. 4B). In the corresponding lysates, only one
single band representing the FL Bri2KR/AA protein was
detected (Fig. 4B), confirming that propeptide cleavage was
abolished in themutant Bri2 variant. Themutant Bri2 substrate
was then co-expressed with SPPL2b and the inactive SPPL2b
D/A mutant (Fig. 4C). Secretion of the BRICHOS domain
(including the propeptide) was independent of the biological
activity of SPPL2b (Fig. 4C). Thus these data demonstrate that
shedding of Bri2 by ADAM10 occurs independent of furin-
mediated processing. Moreover, furin-mediated processing of
Bri2 was not required for its subsequent intramembrane prote-
olysis by SPPL2b as demonstrated by the ICD generation in Fig.
4C. This was also supported by the accumulation of the Bri2
NTF upon expression of the catalytically inactive SPPLb D/A
mutant (Fig. 4C).
Subcellular Localization of Bri2 and SPPL2b—The above
described results demonstrate that preferentially SPPL2a and
SPPL2b process Bri2. To investigate in which cellular compart-
ment Bri2 and SPPL2b interact, we performed immunocyto-
chemical experiments. Bri2 and SPPL2b co-localize within a
vesicular structure close to the nucleus (Fig. 5A). Co-local-
ization studies using antibodies against the V5 or HA tag (for
Bri2 or SPPL2b, respectively) and Giantin revealed that the
protease and its substrate are both
co-expressed within the Golgi (Fig.
5A). Additional co-staining within
later secretory compartments, like
endosomes, cannot be excluded.
This suggests that proteolytic proc-
essing of Bri2 may be initiated upon
its arrival in the Golgi. However, co-
localization by itself is not sufficient
for RIP of Bri2. This is demon-
strated by BFA treatment that
blocks forward transport from the
ER to the Golgi (44). Under these
conditions, SPPL2b and Bri2 fully
co-localize within an ER/Golgi
fusion compartment (Fig. 5B).
Interestingly, the co-localization
under these conditions does not
allow processing of Bri2 by SPPL2b
because production of the Bri2 ICD
is blocked (Fig. 5C). Consistent with
previous findings, furin-mediated
processing was also abrogated
under these conditions (40) as dem-
onstrated by the accumulation of
pro-Bri2 in the cell lysate (Fig. 5, C and D). Upon BFA treat-
ment, we were also not able to detect the propeptide in either
the medium or the corresponding lysate (Fig. 5D). In addition,
BFA treatment of cells expressing Bri2FC (see Fig. 2A)
reduced the secretion of the BRICHOS domain below the
detection level, and the BRICHOS domain was also not
detected in the corresponding lysate (Fig. 5E). Taken together,
these data suggest that co-localization of Bri2 with its proteases
alone is not sufficient for RIP of Bri2.
DISCUSSION
We have demonstrated that Bri2 is a novel substrate for RIP.
In contrast to previous knowledge, we could demonstrate that
Bri2 is processed not only by furin or related proteases but also
byADAM10 and SPPL2a/SPPL2b (Fig. 6). TheADAM10 cleav-
age liberates the BRICHOS domain, which, like the ectodo-
mains of many other proteins, is secreted. The function of the
BRICHOSdomain is unclear (45). Interestingly, the Bri2 homo-
logues, Bri1 andBri3 (Itm2Aand Itm2C, respectively), also con-
tain a conserved BRICHOS domain. Whether BRICHOS is
secreted in these proteins remains to be verified. The secretion
of the complete Bri2 BRICHOS domain strongly suggests that
this domainmay have a physiological functionwithin the extra-
cellular space and probably even far away from its producing
cell. Moreover, in analogy to Notch signaling, onemay expect a
receptor/ligand interaction inducing shedding and intramem-
brane proteolysis (46). Interestingly, proteolytic processing of
Notch and Bri2 share some remarkable similarities. Both con-
tain a propeptide that is removed by furin or related proteases
(32, 33, 46). Furthermore, in both cases, the ectodomain under-
goes shedding via a protease of the ADAM family (46). Finally,
both proteins undergo intramembrane proteolysis to produce










































































FIGURE 4. Shedding by ADAM10 and intramembrane cleavage by SPPL2b occur independently of a prior
cleavage of Bri2 by furin. A, schematic presentation of Bri2KR/AA. The residues Lys-243 and Arg-244 were
both mutated to alanine, resulting in a furin-uncleavable Bri2 variant. B, Bri2KR/AA was not processed by furin.
Cells stably expressing the indicated Bri2 variants were analyzed for the indicated cleavage products as
described in the legend to Fig. 3C. In cell lines expressing Bri2KR/AA, the BRICHOS domain containing the
uncleaved propeptide was secreted into the conditioned medium, whereas no liberated propeptide was
detected. In cell lines expressing wild-type (wt) Bri2, the secreted BRICHOS domain was not detected because
the V5 tag was removed by furin-mediated processing. In cell lysates, Bri2KR/AA was detected as a single
protein of 50 kDa, indicating that Bri2KR/AA cannot be processed by furin. C, Bri2KR/AA was processed by
SPPL2b and ADAM10. Cells stably expressing the indicated SPLL2b variants and Bri2KR/AA were analyzed for
the indicated processing products as described in the legend to Fig. 3C. In all cell lines, the BRICHOS domain
containing the uncleaved propeptide was secreted into the conditioned media. In cells expressing the active
SPPL2b, the Bri ICD (10 kDa) was detected additionally. Asterisk indicates longer blot exposure.
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Intramembrane proteolysis is again mediated by proteases of
the same family, theGXGDproteases. Although these are strik-
ing similarities, some obvious differences are observed as well.
The substrate proteins, such as Notch and Bri2, have opposite
membrane orientation. This is reflected by the corresponding
orientations of the catalytically active sites within presenilin
and the SPPL2 (1, 15). Furthermore, -secretase is a protein
complex that absolutely requires four components for its activ-
ity (48), whereas SPP and SPPLs apparently do not (29, 37). This
is even more surprising if one compares the very similar proc-
essing pathways of Notch and Bri2. One of the components of
the -secretase complex, nicastrin, is required as a substrate-
docking site, which accepts only previously shedded substrates
(49). Shedding also occurs for Bri2, and we could demonstrate
that the NTF of Bri2 co-isolates with SPPL2a/SPPL2b. How-
ever, in contrast to -secretase, which does not bind full-length
substrate (50, 51), we and others (29, 30) found that the full-
length substrates (Fas ligand, Bri2, and TNF) also co-precipi-
tate with SPPL2a/SPPL2b. Apparently, the NTF is preferen-
tially turned over because relatively low levels are bound to
proteolytically active SPPL2a/SPPL2b, as compared with the
full-length protein (see Fig. 3D and Ref. 29). In contrast,
when proteolytically inactive SPPL2a/SPPL2b variants are
expressed, higher levels of the NTF co-precipitate (see Fig.
3D and Ref. 29). This suggests that NTFs may be the pre-
ferred substrates of SPPL2a/SPPL2b. However, because of
the potential lack of an additional cofactor such as nicastrin,
less preferred full-length substrates were also bound. One
may hypothesize that processing of such longer substrates
could apparently be less efficient. Therefore, proteins like
nicastrin may have evolved to exclude their binding. In addi-




































































FIGURE 5. Subcellular localization of Bri2 and SPPL2b. A, co-localization of Bri2 and SPPL2b. HEK293 cells stably expressing SPPL2b and Bri2 were stained
with antibodies against the HA or V5 tag, respectively. Bri2 and SPPL2b are co-localized. SPPL2b as well as Bri2 partially co-stain in the same subcellular structure
with the Golgi resident protein Giantin, indicating that SPPL2b and Bri2 interact in the Golgi. B, co-localization of Bri2 and SPPL2b in BFA-treated cells. Cells
described in A were treated with 10 g/l BFA overnight and stained as described in A. Co-staining of SPPL2b and Bri2 was observed in an ER/Golgi fusion
compartment that surrounds the nucleus. The scale bars in A and B indicate 10 m. C, SPPL2b cleavage was inhibited upon BFA treatment. Cell lysates of cells
stably expressing SPPL2b and Bri2 were analyzed for Bri2 fragments using the anti-FLAG antibody. Upon BFA treatment, pro-Bri2 accumulates, whereas Bri2
and Bri2 ICD are no longer produced (asterisk indicates longer blot exposure). D, lack of furin cleavage of Bri2 in BFA-treated cells. Cells stably expressing SPPL2b
and Bri2 were treated with BFA or carrier only (control) as described in B. Upon BFA treatment, pro-BRi2 accumulates (as also shown in C). Consistent with the
accumulation of pro-Bri2 in cell lysates, no propeptide was detected in either cell lysates or the corresponding conditioned media. E, ADAM10 does not cleave
Bri2 in BFA-treated cells. Cells stably expressing Bri2FC were treated as described in the legend Fig. 3C, and the indicated processing products of Bri2 were
analyzed. Note that BFA treatment blocks BRICHOS generation in the conditioned medium as well as in the corresponding lysates, indicating that ADAM10
does not cleave Bri2 under these conditions.
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that could transfer the substrate from the docking site to the
catalytic center may have evolved. These proteins could be
represented by PEN-2 and APH-1 (20).
Anothermajor question is how substrates are selectively rec-
ognized by the SPP family members because Fas ligand, TNF,
and Bri2 are preferentially processed by SPPL2a and SPPL2b
but not by the highly similar SPP or SPPL3 (29, 30) (Fig. 3C).
This may be explained by their differential subcellular localiza-
tion (26). Although SPP and SPPL3 are restricted to the endo-
plasmic reticulum, SPPL2a/SPPL2b occur in theGolgi and later
secretory compartments such as endosomes/lysosomes (26,
27). Thus the spatial separation of the enzymes and their
substrates may contribute to substrate selectivity. However,
co-localization by itself is not sufficient for the processing of
Bri2 by SPPL2b as demonstrated by the complete inhibition
of Bri2 ICD generation upon BFA treatment. Because under
these conditions propeptide removal and ectodomain shed-
ding are blocked as well, this suggests three possible expla-
nations for the lack of proteolytic activity of SPPL2b in this
compartment: 1) maturation and folding of SPPL2b is
incomplete in the ER/Golgi fusion compartment, 2) the pH
in this artificial compartment is not optimal for SPPL2b
activity, or 3) Bri2 NTF and not Bri2 itself is the preferred
substrate for SPPL2b cleavage.
RIP is becoming an increasingly important cellular pathway
as the liberated ICDs may have important functions in cellular
signaling. The perhaps best understood example is the RIP of
Notch, in which the Notch ICD serves as a transcription factor
(46). It will be important to determine whether the Bri2 ICD
also serves as a part of a signaling cascade. Besides signaling,
intramembrane proteolysis also plays a major role in the
removal and subsequent degradation of membrane-retained
fragments, which are produced by the initial shedding event
(52). A similar membrane proteasome-like function may be
taken over by some SPP family members to remove type II-
oriented stubs from membranes.
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